★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
GSK plc (GSK) Moat Analysis
GSK plc
GSK · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
GSK is a global biopharma company focused on Specialty Medicines, Vaccines and General Medicines. In H1 2026, the businesses generated about 43.7%, 27.6% and 28.7% of turnover respectively. The demonstrated moat is time-bounded patent, regulatory and licensed exclusivity around products such as Dovato, Shingrix, Arexvy and Trelegy. Specialty growth is broad, but management is explicitly preparing for the 2028-2030 dolutegravir loss-of-exclusivity period; Trelegy also faces current generic patent challenges. Inhaler retraining is category-level friction shared with rivals, not a separate GSK switching-cost moat. Pricing power is moderate in Specialty and Vaccines but weak in General Medicines given direct evidence of payer, channel, tender and generic pressure.
Primary segment
Specialty Medicines
Market structure
Competitive
Market share
—
HHI: —
Coverage
3 segments · 5 tags
Updated 2026-08-23
Segments
Vaccines
Human vaccines
Revenue
27.6%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Specialty Medicines
Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)
Revenue
43.7%
Structure
Competitive
Pricing
moderate
Share
—
Peers
General Medicines
Respiratory inhaled therapies and established branded medicines
Revenue
28.7%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
Vaccines
Human vaccines
H1 2026 Vaccines turnover was GBP 4.433bn / total turnover GBP 16.038bn, up 6% CER. Shingrix was GBP 1.914bn (+12% CER), meningitis GBP 797m (+9%) and Arexvy GBP 257m (+75%). Q2 product commentary shows demand, tender deliveries, channel inventory and rebate adjustments all affect sales.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivities protect differentiated adult vaccines, but the portfolio is mixed: Shingrix protection is listed through 2029 in the US and 2031 in the EU, Arexvy through 2030 and 2032, while several older vaccines are expired.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry and biosimilar/next-gen vaccine entry
- Competitors improving safety/efficacy profiles
- Government tender pricing reducing returns despite IP
Leading indicators
- Competitor trial readouts in overlapping indications
- Patent challenges or adverse litigation outcomes
- ACIP/EMA label and recommendation changes
Counterarguments
- Vaccine IP does not guarantee sustained share if rivals launch better products
- Tender-driven markets can commoditize even differentiated vaccines
Specialty Medicines
Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)
H1 2026 Specialty Medicines turnover was GBP 7.008B of GBP 16.038B group turnover, up 14% at constant exchange rates. HIV was GBP 3.902B, respiratory and immunology was GBP 2.025B and oncology was GBP 1.081B. Product demand, reimbursement and channel mix explain the growth better than market concentration.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and licensed rights restrict direct copies of GSK specialty assets across HIV, respiratory/immunology and oncology. The protection is valuable but time-bounded, with management explicitly planning around dolutegravir loss of exclusivity in 2028-2030.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity and generic/biosimilar entry
- Price controls and reimbursement tightening
- Clinical differentiation narrowing vs competitors
Leading indicators
- Patent litigation outcomes and generic filing activity
- Payer/formulary moves against branded regimens
- Share shifts in HIV and oncology classes
Counterarguments
- Even under patent, payers can steer volume to alternatives
- Pipeline execution is required to replace revenue at LOE
General Medicines
Respiratory inhaled therapies and established branded medicines
H1 2026 General Medicines turnover was GBP 4.597bn / total turnover GBP 16.038bn, down 7% CER. Respiratory was GBP 3.273bn (-7%) and Trelegy GBP 1.421bn (-3%). Inhaler retraining may create category-level friction, but it is shared by competitors and can be overridden by payers, so it is not scored as a GSK-specific switching-cost moat.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Trelegy retains listed patent protection, but its base patents approach expiry and proposed generics now challenge Orange Book-listed patents. Most older General Medicines products have weaker or expired protection.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry and generic/biosimilar entry
- Device patent workarounds by competitors
- Pricing pressure via payer rebates
Leading indicators
- Patent challenges and settlements
- Competitor inhaler launches and generic approvals
- Net price trends (rebate/discount intensity)
Counterarguments
- Even with patents, payers can compress net pricing through rebates
- Competitors can launch therapeutically similar combinations
Evidence
Patent expiry dates in normal text relate to the latest expiring new molecular entity patents
The product table lists Shingrix expiry in 2029/2031 and Arexvy in 2030/2032 for the US/EU respectively; multiple established vaccines are already expired.
dolutegravir patent expiry period (2028-2030)
Management is reallocating resources and targeting savings partly to protect profitability through the principal HIV loss-of-exclusivity period. The 2025 patent table lists Dovato base patent expiry in 2028/2029 and other patents into the 2030s.
asserting infringement of the five Orange Book listed patents
GSK filed US suits in March and June 2026 after Transpire sought approval for proposed generic Trelegy 100mcg and 200mcg products. The 2025 table lists Trelegy base patent expiry in 2027/2029 and other patents into 2031/2032 in the US/EU.
Risks & Indicators
Erosion risks
- Patent expiry and biosimilar/next-gen vaccine entry
- Competitors improving safety/efficacy profiles
- Government tender pricing reducing returns despite IP
- Loss of exclusivity and generic/biosimilar entry
- Price controls and reimbursement tightening
- Clinical differentiation narrowing vs competitors
Leading indicators
- Competitor trial readouts in overlapping indications
- Patent challenges or adverse litigation outcomes
- ACIP/EMA label and recommendation changes
- Patent litigation outcomes and generic filing activity
- Payer/formulary moves against branded regimens
- Share shifts in HIV and oncology classes
Research GSK elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.